Neogenomics Inc [NEO] stock is trading at $6.24, down -7.14%. An important factor to consider is whether the stock is rising or falling in short-term value. The NEO shares have lost -14.05% over the last week, with a monthly amount drifted -10.73%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Leerink Partners downgraded its rating to Market Perform on April 30, 2025, and kept the price target unchanged to $9. On January 13, 2025, downgrade downgraded it’s rating to Hold. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $22 on December 10, 2024. BTIG Research reiterated a Buy rating for this stock on December 29, 2023, and downed its price target to $21. In a note dated August 21, 2023, Stephens upgraded an Overweight rating on this stock but restated the target price of $18.
Neogenomics Inc [NEO] stock has fluctuated between $6.08 and $19.11 over the past year. Currently, Wall Street analysts expect the stock to reach $12 within the next 12 months. Neogenomics Inc [NASDAQ: NEO] shares were valued at $6.24 at the most recent close of the market. An investor can expect a potential return of 92.31% based on the average NEO price forecast.
Analyzing the NEO fundamentals
Neogenomics Inc [NASDAQ:NEO] reported sales of 672.36M for the trailing twelve months, which represents a growth of 7.55%. Gross Profit Margin for this corporation currently stands at 0.44% with Operating Profit Margin at -0.13%, Pretax Profit Margin comes in at -0.12%, and Net Profit Margin reading is -0.12%. To continue investigating profitability, this company’s Return on Assets is posted at -0.05, Equity is -0.09 and Total Capital is -0.07. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.68.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.04 points at the first support level, and at 5.85 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.61, and for the 2nd resistance point, it is at 6.99.
Ratios To Look Out For
For context, Neogenomics Inc’s Current Ratio is 2.05. On the other hand, the Quick Ratio is 1.94, and the Cash Ratio is 1.24. Considering the valuation of this stock, the price to sales ratio is 1.19, the price to book ratio is 0.90.
Transactions by insiders
Recent insider trading involved Kelly Michael Aaron, Director, that happened on May 27 ’25 when 5000.0 shares were purchased. Pres & Chief Operating Officer, Stone Warren completed a deal on May 12 ’25 to buy 5700.0 shares. Meanwhile, Director TETRAULT LYNN A. bought 7000.0 shares on May 09 ’25.
